Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 176 in Relapsed/Refractory MM and AML
NCT02675452Phase 1Terminated
- Sponsor
- Amgen
- Start
- Jun 2016
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of Tapotoclax in multiple myeloma (MM) and acute myeloid leukemia (AML) (8 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment-emergent Adverse Events and 6 more. Started Jun 2016; status: terminated.
02
Drugs
Tapotoclax
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02675452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675452.